Pilot Study on MAGE-C2 as a Potential Biomarker for Triple-Negative Breast Cancer

Zhao, Qian; Xu, Wei; Shalieer, Tuluhong

doi:10.1155/2016/2325987

Cited by 12 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MAGE-C2 was abnormally expressed in non-small cell lung cancer and correlated with the prognosis [ 18 ]. MAGE-C2 could also serve as a biomarker for triple-negative breast cancer, TNBC [ 19 ]. Interestingly, MAGE-C2-specific TCRs could also affect cancer progression [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: MAGE-C2/CT10 promotes growth and metastasis through upregulating c-Myc expression in prostate cancer

Qiu

Yang

2020

Mol Cell Biochem

View full text Add to dashboard Cite

Prostate cancer (PC) is the most common reproductive cancer in men and the third leading cause of cancer death among men worldwide. Recently targeted therapy showed a significant therapeutic effect on PC, whereas finding more PC therapeutic target is still urgently needed. Melanoma-associated antigen-encoding C2 (MAGE-C2/CT10), which have significant homology with the MAGE-C1/CT-7 gene, was known to be involved in the development of a variety of tumors. However, the role and mechanism of MAGE-C2/CT10 in prostate cancer remains unclear. Herein, we found the high levels of MAGE-C2/CT10 in highly metastatic prostate cancer. Our findings confirmed that the depletion of MAGE-C2/CT10 suppressed the growth of PC cells, and restrained PC cell migration and invasion in vitro. We noticed MAGE-C2/CT10 could stimulate c-Myc expression via FBP1, and further contributed to PC cell proliferation and motility. Performing in vivo assays, we demonstrated MAGE-C2/CT10 promoted tumor growth and metastasis of PC cells in mice. Collectively, we found the abnormal expression of MAGE-C2/CT10 in PC, and revealed the regulatory mechanism underlying MAGE-C2/CT10 promoting PC progression and metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: MAGE-C2/CT10 promotes growth and metastasis through upregulating c-Myc expression in prostate cancer

Qiu

Yang

2020

Mol Cell Biochem

View full text Add to dashboard Cite

show abstract

“…Collective studies support the notion that elevated MAGEC2 expression can be observed in different cancers19,20 and that MAGEC2 expression is correlated with several important clinicopathological attributes, including tumour size,21 TNM stage,8 and recurrence 22. Moreover, Zhao et al9 and Figueiredo et al8 described the prognostic role of MAGEC2 in breast cancer and larynx cancer, respectively. Our data are in accordance with the findings of these previous studies.…”

Section: Discussionmentioning

confidence: 82%

“…A high incidence of MAGEC2 expression has been reported in larynx squamous cell carcinoma and is remarkably correlated with an advanced clinical stage 8. A recent pilot study also reported that MAGEC2 could be a potential biomarker for triple-negative breast cancer 9. However, the detailed characteristics and mechanisms of MAGEC2 in HCC are inadequately understood.…”

Section: Introductionmentioning

confidence: 99%

<p>MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition</p>

Yuan

Shi

et al. 2019

OTT

View full text Add to dashboard Cite

PurposeAlthough MAGEC2 was first cloned from a human hepatocellular carcinoma (HCC) cDNA library by serum screening, the detailed attributes of MAGEC2 in HCC have rarely been elucidated.Patients and methodsIn this study, The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases were consulted to analyse the expression of MAGEC2 mRNA in liver cancer. Immunohistochemistry (IHC) analysis was performed to detect MAGEC2 expression in HCC, and the relationship between MAGEC2 expression and the clinicopathological characteristics of HCC patients was evaluated. Then, we employed the short hairpin (sh)RNA-mediated knockdown of MAGEC2 in HCC cell lines to explore the function of MAGEC2 in HCC development. Finally, the expression of epithelial-mesenchymal transition (EMT) markers in HCC xenografts and clinical samples was investigated.ResultsThe results showed a remarkably higher level of MAGEC2 expression in HCC tissues than in noncancerous tissues, and MAGEC2 expression could be used as an independent prognostic factor for overall survival in HCC. Moreover, sh-MAGEC2 inhibited a series of HCC malignant behaviours both in vitro and in vivo. Finally, decreased MAGEC2 expression and low levels of EMT markers were detected in sh-MAGEC2 xenografts, while increased MAGEC2 expression and high levels of EMT markers were observed in invasive and metastatic HCC samples.ConclusionTaken together, our data imply that MAGEC2 is a novel prognostic marker for HCC and that MAGEC2 significantly promotes HCC tumourigenesis by inducing EMT. Targeting MAGEC2 may provide a promising therapeutic strategy for HCC treatment.

show abstract

“…MAGEC2 belongs to the MAGE family which codes for cancer-testis antigen. They are located on the X chromosome and involved in normal tissue development as well as in tumorigenesis of various tumors [ 38 , 39 ]. MAGEC2 expression is restricted to male germ cells and is not found in adult somatic cells.…”

Section: Introductionmentioning

confidence: 99%

In Search of TGCT Biomarkers: A Comprehensive In Silico and Histopathological Analysis

et al. 2020

View full text Add to dashboard Cite

Testicular germ cell tumors (TGCTs) are ever more affecting the young male population. Germ cell neoplasia in situ (GCNIS) is the origin of TGCTs, namely, seminomas (SE) and a heterogeneous group of nonseminomas (NS) comprising embryonal carcinoma, teratoma, yolk sac tumor, and choriocarcinoma. Response to the treatment and prognosis, especially of NS, depend on precise diagnosis with a necessity for discovery of new biomarkers. We aimed to perform comprehensive in silico analysis at the DNA, RNA, and protein levels of six prospective (HOXA9, MGMT, CFC1, PRSS21, RASSF1A, and MAGEC2) and six known TGCT biomarkers (OCT4, SOX17, SOX2, SALL4, NANOG, and KIT) and assess its congruence with histopathological analysis in all forms of TGCTs. Cancer Hallmarks Analytics Tool, the Search Tool for the Retrieval of Interacting Genes/Proteins database, and UALCAN, an interactive web resource for analyzing cancer OMICS data, were used. In 108 TGCT and 48 tumor-free testicular samples, the immunoreactivity score (IRS) was calculated. SE showed higher frequency in DNA alteration, while DNA methylation was significantly higher for all prospective biomarkers in NS. In GCNIS, we assessed the clinical positivity of RASSF1 and PRSS21 in 52% and 62% of samples, respectively, in contrast to low or nil positivity in healthy seminiferous tubules, TGTCs as a group, SE, NS, or all NS components. Although present in approximately 80% of healthy seminiferous tubules (HT) and GCNIS, HOXA9 was diagnostically positive in 64% of TGCTs, while it was positive in 82% of NS versus 29% of SE. Results at the DNA, mRNA, and protein levels on putative and already known biomarkers were included in the suggested panels that may prove to be important for better diagnostics of various forms of TGCTs.

show abstract

Pilot Study on MAGE-C2 as a Potential Biomarker for Triple-Negative Breast Cancer

Cited by 12 publications

References 26 publications

RETRACTED ARTICLE: MAGE-C2/CT10 promotes growth and metastasis through upregulating c-Myc expression in prostate cancer

RETRACTED ARTICLE: MAGE-C2/CT10 promotes growth and metastasis through upregulating c-Myc expression in prostate cancer

<p>MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition</p>

In Search of TGCT Biomarkers: A Comprehensive In Silico and Histopathological Analysis

Contact Info

Product

Resources

About